2-acetyl-3,4-dihydro-1H-isoquinoline-7-carbonitrile | 916210-07-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-acetyl-3,4-dihydro-1H-isoquinoline-7-carbonitrile
• CAS: 916210-07-6
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: CGHQPDRUMWALJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-acetyl-3,4-dihydro-1H-isoquinoline-7-carbonitrile 、 二碳酸二叔丁酯 在 nickel dichloride sodium tetrahydroborate 、 二乙烯三胺 、 citric acid 、 碳酸氢钠 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 0.5h， 生成 tert-butyl N-[(2-acetyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]carbamate
  参考文献：
  名称：

  Multicyclic bis-amide MMP inhibitors

  摘要：

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。

  公开号：

  US20060173183A1
• 作为产物：
  描述：

  1,2,3,4-四氢异喹啉-7-甲腈 在 吡啶 、 乙酸酐 作用下， 生成 2-acetyl-3,4-dihydro-1H-isoquinoline-7-carbonitrile
  参考文献：
  名称：

  WO2006/128184

  摘要：

  公开号：

文献信息

• Dual Ligand-Enabled Nondirected C–H Cyanation of Arenes
  作者：Hao Chen、Arup Mondal、Philipp Wedi、Manuel van Gemmeren

  DOI：10.1021/acscatal.8b04639

  日期：2019.3.1

  structural units in organic chemistry and, therefore, highly attractive targets for C–H activation. Herein, the development of an arene-limited, nondirected C–H cyanation based on the use of two cooperatively acting commercially available ligands is reported. The reaction enables the cyanation of arenes by C–H activation in the absence of directing groups and is therefore complementary to established

  芳香腈是有机化学中的关键结构单元，因此是C–H活化的极具吸引力的目标。在此，据报道，基于使用两种可协同作用的市售配体，开发了一种受芳烃限制的，无方向性的CH氰基氰化反应。该反应可在没有导向基团的情况下通过C–H活化使芳烃氰化，因此可与已建立的方法互补。
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• SEPIAPTERIN REDUCTASE INHIBITORS
  申请人：QUARTET MEDICINE, INC.

  公开号：US20170096435A1

  公开（公告）日：2017-04-06

  Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.